cilostazol has been researched along with Cerebral Microangiopathies in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To test the feasibility, drug tolerability, safety, and effects of 1-year isosorbide mononitrate (ISMN) and cilostazol treatment on vascular, functional, and cognitive outcomes in patients with lacunar stroke." | 5.69 | Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial. ( Bamford, J; Bath, PM; Cvoro, V; Doubal, FN; England, T; Hassan, A; Heye, AK; Mhlanga, II; Montgomery, A; O'Brien, JT; Oatey, K; Roffe, C; Sprigg, N; Wardlaw, JM; Werring, DJ; Woodhouse, LJ, 2023) |
| "Cerebral small vessel disease is characterized by progressive cerebral white matter changes (WMCs)." | 3.11 | Cilostazol Versus Aspirin on White Matter Changes in Cerebral Small Vessel Disease: A Randomized Controlled Trial. ( Cho, SJ; Choi, SH; Choi, YH; Han, HJ; Jeong, JH; Kim, BC; Kim, EJ; Kim, JH; Kim, S; Lee, JH; Lee, JM; Na, DL; Oh, MS; Park, G; Park, HY; Park, KC; Park, KH; Park, KW; Park, SA; Shim, Y; Yoon, B; Yoon, SJ; Youn, YC, 2022) |
| "Cilostazol treatment improved BBB permeability and reduced gait disturbance, visual impairment and microglial activation in optic tract following BCCAO in vivo." | 1.43 | Cilostazol reduces blood brain barrier dysfunction, white matter lesion formation and motor deficits following chronic cerebral hypoperfusion. ( Cadonic, R; Edrissi, H; Hakim, AM; Schock, SC; Thompson, CS, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, BC | 1 |
| Youn, YC | 1 |
| Jeong, JH | 1 |
| Han, HJ | 1 |
| Kim, JH | 1 |
| Lee, JH | 1 |
| Park, KH | 1 |
| Park, KW | 1 |
| Kim, EJ | 1 |
| Oh, MS | 1 |
| Shim, Y | 1 |
| Lee, JM | 1 |
| Choi, YH | 1 |
| Park, G | 1 |
| Kim, S | 1 |
| Park, HY | 1 |
| Yoon, B | 1 |
| Yoon, SJ | 1 |
| Cho, SJ | 1 |
| Park, KC | 1 |
| Na, DL | 1 |
| Park, SA | 1 |
| Choi, SH | 1 |
| Blair, GW | 2 |
| Janssen, E | 1 |
| Stringer, MS | 1 |
| Thrippleton, MJ | 2 |
| Chappell, F | 1 |
| Shi, Y | 2 |
| Hamilton, I | 2 |
| Flaherty, K | 2 |
| Appleton, JP | 2 |
| Doubal, FN | 2 |
| Bath, PM | 4 |
| Wardlaw, JM | 4 |
| Mhlanga, I | 1 |
| Woodhouse, LJ | 2 |
| Doubal, F | 2 |
| Oatey, K | 2 |
| Montgomery, AA | 1 |
| Mhlanga, II | 1 |
| Heye, AK | 1 |
| Bamford, J | 1 |
| Cvoro, V | 1 |
| England, T | 1 |
| Hassan, A | 1 |
| Montgomery, A | 1 |
| O'Brien, JT | 1 |
| Roffe, C | 1 |
| Sprigg, N | 2 |
| Werring, DJ | 1 |
| Law, ZK | 1 |
| Dooley, R | 1 |
| Shuler, K | 1 |
| Richardson, C | 1 |
| Stringer, M | 1 |
| Boyd, J | 1 |
| Edrissi, H | 1 |
| Schock, SC | 1 |
| Cadonic, R | 1 |
| Hakim, AM | 1 |
| Thompson, CS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double Blind Study to Compare the Efficacy Between Cilostazol and Aspirin on White Matter Changes by Cerebral Small Vessel Disease[NCT01932203] | Phase 4 | 255 participants (Actual) | Interventional | 2013-07-17 | Active, not recruiting | ||
| Preventing Cognitive Decline and Dementia From Cerebral Small Vessel Disease[NCT02481323] | Phase 2 | 57 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for cilostazol and Cerebral Microangiopathies
1 other study available for cilostazol and Cerebral Microangiopathies
| Article | Year |
|---|---|
Cilostazol reduces blood brain barrier dysfunction, white matter lesion formation and motor deficits following chronic cerebral hypoperfusion.
Topics: Animals; Blood-Brain Barrier; Cell Survival; Cerebral Small Vessel Diseases; Cilostazol; Disease Mod | 2016 |